Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct;152(3):313-22.
doi: 10.1038/sj.bjp.0707398. Epub 2007 Jul 23.

The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1

Affiliations

The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1

V Raoch et al. Br J Pharmacol. 2007 Oct.

Abstract

Background and purpose: CGS-26303 inhibits endothelin converting enzyme (ECE)-1 more specifically than phosphoramidon. We have studied the effect of CGS-26303 on ECE-1 expression in bovine aortic endothelial cells.

Methods: ECE-1 activity and big endothelin (ET)-1 levels were measured by ELISA, ECE-1 expression using western and northern blot and promoter activity using transfection assays.

Key results: ECE-1 activity was completely inhibited by CGS-26303 25 microM and phosphoramidon 100 microM. CGS-26303 and phosphoramidon, though not thiorphan, a neutral endopeptidase (NEP) inhibitor, stimulated ECE-1 expression in cells (maximal effect at 16 h, 25 microM). Cycloheximide abolished that effect. CGS-26303 induced ECE-1 mRNA expression and ECE-1 promoter activity. CGS-35066, a selective ECE-1 inhibitor, mimicked the effects of CGS-26303, suggesting that the effect was specific to ECE-1 inhibition. Big ET-1 accumulated in the cells and in the supernatants after CGS-26303 treatment. Neither exogenously added ET-1 nor the blockade of their receptors with bosentan modified ECE-1 protein. When big ET-1 was added to cells, significant increases in ECE-1 protein content and ECE-1 promoter activity were found. Bosentan did not block those effects. CGS-26303 did not modify prepro-ET-1 expression. CGS-26303 and big ET-1 induced the same effects in human endothelial cells, at lower doses.

Conclusions: These results suggest that the accumulation of big ET-1 is responsible for the effects of CGS-26303 on ECE-1 and they did not depend on NEP blockade. Changes in ECE-1 protein after the administration of CGS-26303 could lead to a decreased response in long-term treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of CGS-26303 on ECE-1 activity and ECE-1 protein content. (a) Cell extracts from BAEC were incubated with different concentrations of CGS-26303 for 6 h and ECE-1 activity was measured. 100 μM phosphoramidon (PP) was used as an internal control. Results are the mean value±s.e. mean of four independent experiments. *P<0.05 vs control values (C). (b) BAEC were incubated for 16 h with 25 μM CGS-26303, 100 μM PP, and 10 μM thiorphan (TP). A representative western blot is shown in the upper part of the panel, whereas in the lower part, the densitometric analysis of three independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (C). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; PP, phosphoramidon; TP, thiorphan.
Figure 2
Figure 2
Effect of CGS-26303 on ECE-1 protein content. BAEC were incubated for different periods of time with 25 μM CGS-26303 (a), or with different concentrations of CGS-26303 for 16 h (b). A representative western blot is shown in the upper part of each panel, whereas in the lower part, the densitometric analysis of five independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (C). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1.
Figure 3
Figure 3
Mechanisms involved in the CGS-26303-dependent upregulation of ECE-1. Importance of protein synthesis, mRNA expression and mRNA stability. (a) BAEC were incubated with 25 μM CGS-26303 for different periods of time in basal conditions or in the presence of 1 μM cycloheximide (CHX). A representative western blot is shown above the densitometric analysis of three independent experiments (mean value±s.e. mean). *P<0.05 vs control cells (C). (b) BAEC were incubated with different concentrations of CGS-26303 for 8 h. A representative northern blot is shown in the upper part of the panel, whereas in the lower part, the densitometric analysis of three independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control cells (C). (c) BAEC were incubated with actinomycin D (Act D) (10 μg ml−1) with and without 25 μM CGS-26303, at different times. The mean values of mRNA levels in three independent experiments are shown (mean value±s.e. mean). Act D alone; Act D+CGS-26303. Act D, actinomycin D; BAEC, bovine aortic endothelial cells; CHX, cycloheximide; ECE-1, endothelin converting enzyme-1.
Figure 4
Figure 4
Mechanism involved in the CGS-26303-dependent upregulation of ECE-1. Importance of ECE-1 promoter activation. BAEC were incubated for different periods of time with 25 μM CGS-26303 (a), or with different concentrations of CGS-26303 for 6 h (b). Results are the mean value±s.e. mean of four independent experiments. *P<0.05 vs control values (C). The stimulation observed with phorbol myristate acetate (PMA; 0.3 μM) for 6 h, which was used as a positive control, was 283±38% (n=4). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; PMA, phorbol myristate acetate.
Figure 5
Figure 5
Effects of CGS-35066 on ECE-1 protein content and ECE-1 promoter activity. (a, b) BAEC were incubated for different periods of time with 5 μM CGS-35066 (a), or with different concentrations of CGS-35066 for 16 h (b). A representative western blot is shown in the upper part of each panel, whereas in the lower part the densitometric analysis of five independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (C). (c) BAEC were incubated with two doses of CGS-35066 and with 25 μM of CGS-26303 for 6 h. Results are the mean value±s.e. mean of three independent experiments. *P<0.05 vs control values (C). The stimulation observed with PMA (0.3 μM) for 6 h, which was used as a positive control, was 349±42% (n=3). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; PMA, phorbol myristate acetate.
Figure 6
Figure 6
Effect of CGS-26303 on big ET-1 levels in cells and supernatants. (a) BAEC were incubated for 16 h with 25 μM CGS-26303, 100 μM phosphoramidon (PP) or 10 μM thiorphan (TP), and big ET-1 was measured in cell supernatants. Results are the mean value±s.e. mean of five independent experiments. *P<0.05 vs control values (C). Big ET-1 concentration was 29±3 fmol ml−1 in control cells. (b) BAEC were incubated for 16 h with 25 μM CGS-26303 and 25 nM big ET-1, and intracellular big ET-1 was measured in cells. *P<0.05 vs control values (C). Intracellular big ET-1 concentration was 25±4 fmol ml−1 mg−1 protein in control cells. BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; ET-1, endothelin-1; PP, phosphoramidon; TP, thiorphan.
Figure 7
Figure 7
Role of ET-1, ET-1 (1–31) and big ET-1 in the CGS-26303-dependent ECE-1 upregulation. (a) BAEC were incubated for different periods of time with 10 nM ET-1 alone, or with 10 nM ET-1, in the absence or presence of 10 μM bosentan for 16 h. A representative western blot is shown in the upper part of the panel, whereas the densitometric analysis of four independent experiments is shown below (mean value±s.e. mean). (b) BAEC were incubated for different periods of time with 10 nM ET-1 (1–31) alone or with 10 nM ET-1 (1–31) for 16 h, in the absence or presence of 10 μM bosentan. A representative western blot is shown in the upper part of the panel, whereas the densitometric analysis of three independent experiments is shown below (mean value±s.e. mean). (C) BAEC were incubated for 16 h in control conditions (C), or with 25 nM big ET-1 or 25 μM CGS-26303 in the absence or presence of 10 μM bosentan. A representative western blot is shown above, whereas in the lower part the densitometric analysis of four independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (c). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; ET-1, endothelin-1.
Figure 8
Figure 8
Effect of big ET-1 on ECE-1 protein content. BAEC were incubated for different periods of time with 25 nM big ET-1 (a) or with different doses of big ET-1 for 16 h (b). A representative western blot is shown in the upper part of each panel, whereas in the lower part the densitometric analysis of four independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (C). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; ET-1, endothelin-1.
Figure 9
Figure 9
Effect of big ET-1 on ECE-1 promoter activity. BAEC were incubated for different periods of time with 25 nM big ET-1 (a) or with different doses of big ET-1 for 6 h (b). Results are the mean value±s.e. mean of four independent experiments. *P<0.05 vs control values (C). The stimulation observed with PMA (0.3 μM) for 6 h, which was used as a positive control, was 272±25% (n=4). BAEC, bovine aortic endothelial cells; ECE-1, endothelin converting enzyme-1; ET-1, endothelin-1; PMA, phorbol myristate acetate.
Figure 10
Figure 10
Effect of CGS-26303 on prepro-ET-1 (ppET-1) mRNA expression. BAEC were incubated for different periods of time with 25 μM CGS-26303 (a) or with different concentrations of CGS-26303 for 16 h (b). A representative northern blot is shown in the upper part of each panel, whereas in the lower part the densitometric analysis of four independent experiments is shown (mean value±s.e. mean). BAEC, bovine aortic endothelial cells; ppET-1, prepro-ET-1.
Figure 11
Figure 11
Effects of CGS-26303, big ET-1 and CGS-35066 on ECE-1 protein content in human endothelial cells (EA.hy926). (a) EA.hy926 were incubated with different compounds, 25 nM big ET-1, 25 μM CGS-26303 and 5 μM CGS-35066 for 16 h. (b) EA.hy926 were incubated with different doses of CGS-26303 for 16 h. A representative western blot is shown in the upper part of each panel, whereas in the lower part the densitometric analysis of four independent experiments is shown (mean value±s.e. mean). *P<0.05 vs control values (C). ECE-1, endothelin converting enzyme-1; ET-1, endothelin-1.

Similar articles

Cited by

References

    1. Aharinejad S, Krenn K, Paulus P, Schafer R, Zuckermann A, Grimm M, et al. Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients. Am J Transplant. 2005;5:2185–2192. - PubMed
    1. Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005;91:825–831. - PMC - PubMed
    1. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol chloroform extraction. Anal Biochem. 1987;162:156–159. - PubMed
    1. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262–15268. - PubMed
    1. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001;89:583–590. - PubMed

Publication types

MeSH terms